BioCentury
DATA GRAPHICS | Data Byte

Fresh polish for 2021’s silver lining as biotech shares tumble again

Valuations slide further: a bargain hunter’s delight?

January 19, 2022 2:51 AM UTC
Updated on Jan 22, 2022 at 2:59 AM UTC

A year of dramatic underperformance by biotech in 2021 had one silver lining, investors told BioCentury for its Financial Markets Preview: it set up the New Year with many public companies’ valuations looking very attractive.

That lining may be shimmering all the brighter after Tuesday’s session, as hopes for a rebound in biotech shares hit another wall when investors returned from the holiday weekend fretting over the pace of anticipated interest rate hikes by the Fed. Indexes would not recover by the end of the week...